~~<i id='3D7BA2598F'><strike id='3D7BA2598F'><tt id='3D7BA2598F'><pre id='3D7BA2598F'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-09-28 17:46:57 Page View：5

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Listen: Biogen's potential pivot, & Illumina's next chapter
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

leisure time

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

A rare thyroid diagnosis led to unexpected, all

Photoillustration:CaseySheneryforSTATAnnieLarsson,40,isnostrangertochronicconditions.Shewasdiagnosed

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

How a small hospital in rural Puerto Rico survived Hurricane Maria

AfterHurricaneMaria,mostresidentsofruralPuertoRicowerewithoutelectricityandcutofffromhealthcare.InMo